New targeted radiation trial hopes to slow resistant prostate cancer

NCT ID NCT06526299

First seen Nov 05, 2025 · Last updated May 20, 2026 · Updated 27 times

Summary

This study tests a radioactive drug, 177Lu-PSMA-617, in 51 men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug seeks out prostate cancer cells and damages their DNA to slow tumor growth. The goal is to see if this treatment can delay cancer progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Olive View-University of California Los Angeles Medical Center

    NOT_YET_RECRUITING

    Sylmar, California, 91342, United States

    Contact

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact

Conditions

Explore the condition pages connected to this study.